SORAFENIB INDUCED ACNEIFORM ERUPTIONS: A CASE REPORT

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2017.v10i4.16805 ◽

2017 ◽

Vol 10 (4) ◽

pp. 6 ◽

Author(s):

Balaji Ommurugan ◽

Amita Priya D ◽

Navin Patil

Keyword(s):

Hepatocellular Carcinoma ◽

Renal Cell Carcinoma ◽

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Drug Reactions ◽

Endothelial Growth Factor ◽

Carcinoma Renal Cell

ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Sorafenib acts by inhibiting various kinases like tyrosine kinase, RET tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis and cell proliferation. Acneiform eruptions are known side effect of EGFR inhibitors with incidence ranging between 20 to 90 percent [3], but acneiform eruptions with Sorafenib is seldom seen. Hence, we report a case of Sorafenib induced acneiform eruptions.Keywords: Sorafenib, EGFR, acneiform eruptions, adverse drug reactions

Download Full-text

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Tyrosine Kinase Inhibitor ◽

Endothelial Growth Factor

Download Full-text

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators

Annals of Oncology ◽

10.1016/s0923-7534(20)33390-1 ◽

2012 ◽

Vol 23 ◽

pp. ix271-ix272

Author(s):

S. Chowdhury ◽

J. Larkin

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The Uk ◽

Endothelial Growth Factor

Download Full-text

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research ◽

10.1158/0008-5472.can-07-5809 ◽

2008 ◽

Vol 68 (12) ◽

pp. 4754-4762 ◽

Author(s):

Caroline A. Heckman ◽

Tanja Holopainen ◽

Maria Wirzenius ◽

Salla Keskitalo ◽

Michael Jeltsch ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

European Journal of Cancer ◽

10.1016/j.ejca.2011.11.027 ◽

2012 ◽

Vol 48 (3) ◽

pp. 333-339 ◽

Author(s):

E. Calvo ◽

B. Escudier ◽

R.J. Motzer ◽

S. Oudard ◽

T.E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Subgroup Analysis ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12423 ◽

2014 ◽

Vol 21 (7) ◽

pp. 741-741

Author(s):

Yoshihiro Wada

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

Endothelial Growth Factor

Download Full-text

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

NMR in Biomedicine ◽

10.1002/nbm.961 ◽

2005 ◽

Vol 18 (5) ◽

pp. 308-321 ◽

Author(s):

Markus Rudin ◽

Paul M. J. McSheehy ◽

Peter R. Allegrini ◽

Martin Rausch ◽

Diana Baumann ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Contrast Agent ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell linesin vitro

BJU International ◽

10.1111/j.1464-410x.2009.08759.x ◽

2010 ◽

Vol 105 (4) ◽

pp. 549-557 ◽

Author(s):

Eva Juengel ◽

Johanna Engler ◽

Ausra Mickuckyte ◽

Jon Jones ◽

Lukasz Hudak ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Carcinoma Cell ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Renal Cell Carcinoma Cell ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2725-8 ◽

2015 ◽

Vol 75 (5) ◽

pp. 1025-1035 ◽

Author(s):

Inkeun Park ◽

Jae-Lyun Lee ◽

Jin-Hee Ahn ◽

Dae-Ho Lee ◽

Kyoo-Hyung Lee ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Treatment Failure ◽

Receptor Tyrosine Kinase ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal Of Pathology ◽

10.2353/ajpath.2008.071074 ◽

2008 ◽

Vol 173 (1) ◽

pp. 265-277 ◽

Author(s):

Cornelia Halin ◽

Hermann Fahrngruber ◽

Josef G. Meingassner ◽

Guido Bold ◽

Amanda Littlewood-Evans ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Skin Inflammation ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Pathology & Oncology Research ◽

10.1007/s12253-017-0323-2 ◽

2017 ◽

Vol 25 (1) ◽

pp. 51-58 ◽

Author(s):

Heounjeong Go ◽

Mun Jung Kang ◽

Pil-Jong Kim ◽

Jae-Lyun Lee ◽

Ji Y. Park ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Cell Carcinoma ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Vegfr Tyrosine Kinase Inhibitor

Download Full-text